Wednesday, September 29, 2010

HCV Predicting Reponders


Soon you may know if you will respond
to treatment before suffering side-effects,
loss of income, and months out of your life.
Merck & Co. has given LabCorp the right to
use the IL-28B polymorphism in a test to
determine whether or not a patient will respond
to treatment with peg-IFN alpha. The
association between response and the polymorphism
was discovered by Merck, and
LabCorp developed the test.


No comments:

Post a Comment